111153-16-3

Usage

Uses

4-(4-Benzyloxyphenyl)benzoic Acid is used as a reactant in the synthesis of HDAC inhibitors.

Upstream product

• 58574-03-1 4'-Hydroxybiphenyl-4-carboxylic acid 
• 100-39-0 benzyl bromide 
• 40501-41-5 methyl 4'-hydroxy-4-biphenylcarboxylate 
• 100-44-7 benzyl chloride 
• 50670-76-3 ethyl 4-hydroxy-4-biphenyl carboxylate 
• 141285-38-3 benzyl 4'-(benzyloxy)biphenyl-4-carboxylate 
• 85683-74-5 benzynyl bromide 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 75472-37-6 4'-benzyloxy-4-biphenylcarboxaldehyde 
• 1263269-29-9 2-ethylbutyl 4'-(benzyloxy)biphenyl-4-carboxylate 
• 128055-22-1 4'-(6-Acryloyloxy-hexyloxy)-biphenyl-4-carboxylic acid 4-((S)-1-difluoromethyl-heptyloxycarbonyl)-phenyl ester 
• 128055-21-0 4'-(6-Acryloyloxy-hexyloxy)-biphenyl-4-carboxylic acid 4-((R)-1-difluoromethyl-heptyloxycarbonyl)-phenyl ester 
• 128083-47-6 (R)-(+)-4-<<<1-(trifluoromethyl)decyl>oxy>carbonyl>phenyl 4'-(benzyloxy)biphenyl-4-carboxylate 
• 128054-87-5 (S)-(-)-4-<<<1-(trifluoromethyl)decyl>oxy>carbonyl>phenyl 4'-(benzyloxy)biphenyl-4-carboxylate 
• 128055-05-0 4'-(8-Acryloyloxy-octyloxy)-biphenyl-4-carboxylic acid 4-((R)-1-trifluoromethyl-heptyloxycarbonyl)-phenyl ester 
• 128055-06-1 4'-(8-Acryloyloxy-octyloxy)-biphenyl-4-carboxylic acid 4-((S)-1-trifluoromethyl-heptyloxycarbonyl)-phenyl ester 
• 128055-12-9 4'-(2-Acryloyloxy-ethoxy)-biphenyl-4-carboxylic acid 4-((R)-1-pentafluoroethyl-heptyloxycarbonyl)-phenyl ester 
• 128055-13-0 4'-(2-Acryloyloxy-ethoxy)-biphenyl-4-carboxylic acid 4-((S)-1-pentafluoroethyl-heptyloxycarbonyl)-phenyl ester 
• 128055-03-8 4'-(6-Acryloyloxy-hexyloxy)-biphenyl-4-carboxylic acid 4-((R)-1-trifluoromethyl-heptyloxycarbonyl)-phenyl ester 
• 128055-04-9 4'-(6-Acryloyloxy-hexyloxy)-biphenyl-4-carboxylic acid 4-((S)-1-trifluoromethyl-heptyloxycarbonyl)-phenyl ester 
• 128054-90-0 (R)-(+)-4-<<<1-(pentafluoroethyl)heptyl>oxy>carbonyl>phenyl 4'-(benzyloxy)biphenyl-4-carboxylate 
• 128054-93-3 (S)-(-)-4-<<<1-(pentafluoroethyl)heptyl>oxy>carbonyl>phenyl 4'-(benzyloxy)biphenyl-4-carboxylate 

Relevant academic research and scientific papers

Regioselective Hydroformylation of Internal and Terminal Alkenes via Remote Supramolecular Control

Regioselective catalytic transformations using supramolecular directing groups are increasingly popular as it allows for control over challenging reactions that may otherwise be impossible. In most examples the reactive group and the directing group are close to each other and/or the linker between the directing group is very rigid. Achieving control over the regioselectivity using a remote directing group with a flexible linker is significantly more challenging due to the large conformational freedom of such substrates. Herein, we report the redesign of a supramolecular Rh–bisphosphite hydroformylation catalyst containing a neutral carboxylate receptor (DIM pocket) with a larger distance between the phosphite metal binding moieties and the DIM pocket. For the first time regioselective conversion of internal and terminal alkenes containing a remote carboxylate directing group is demonstrated. For carboxylate substrates that possess an internal double bond at the Δ-9 position regioselectivity is observed. As such, the catalyst was used to hydroformylate natural monounsaturated fatty acids (MUFAs) in a regioselective fashion, forming of an excess of the 10-formyl product (10-formyl/9-formyl product ratio of 2.51), which is the first report of a regioselective hydroformylation reaction of such substrates.

BIS(HETERO)ARYL CARBOXAMIDE DERIVATIVES FOR USE AS PGI2 ANTAGONISTS

The present invention relates to aryl or heteroaryl amido alkane derivatives of formula (I) wherein R6 represents carboxy or tetrazolyl, which are useful as an active ingredient of pharmaceutical preparations. The aryl or heteroaryl amido alkanes of the present invention have PGI2 antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with PGI2 activity.Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity.The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension;hemophilia and hemorrhage; and inflammation, since the diseases also relate to PGI2.

SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) BENZOHETEROARYL COMPOUNDS

This invention is directed to an (aminoiminomethyl or aminomethyl) benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

Preparation and thermotropic properties of partially fluorinated acrylates

New series of monomers which consist of a 4,4′-biphenyl unit linked to a partially linear fluorinated chain on one side and on the other side to an acrylic part which is either directly connected to the core or separated by an oligomethylene spacer, were

Tetralin compound, liquid crystal material and liquid crystal composition

The invention to provide novel tetralin compounds, liquid crystal materials and liquid crystal compositions, which can constitute a liquid crystal element affording a wide operating temperature range, a high switching speed and a small consumption of elec

Heterocyclic compounds

Biphenylylquinuclidine derivatives of formula I, Q--Ar1 --Ar2, in which Q is of formula Ia or Ib, STR1 in which R1 and R2 are independently selected from hydrogen, alkyl, halogeno and hydroxy; or R1 and R2 when taken together define an oxo group; Xb is selected from --CH2 --, =CH-- and --CH(OH); Xa is selected from --CH2 --, =CH--, CO, --O--, and --S(O)n (wherein n=0, 1 or 2); Ar1 is a phenylene moiety; Ar2 is phenyl; and wherein one or both of Ar1 and Ar2 is optionally unsubstituted or substituted by one or more substituents independently selected from halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, di-alkylamino, N-carbamoyl, N,N-di-alkylcarbamoyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, halogeno-alkyl, alkanoyl and alkanoylamino; and their pharamaceutically acceptable salts are inhibitors of squalene synthase and hence useful in treating diseases and medical conditions in which a lowering of cholesterol is desirable. The use of these derivatives in medicine is disclosed tohether with novel compounds, processes for their preparation and pharmaceutical composition containing them.

Liquid crystal compounds and intermediates thereof

A liquid crystal compound of the formula: STR1 wherein m and n are independently integers of 1 to 22; k and l are independently integers of 1 to 2; and C* is an asymmetric carbon atom, is chemically stable and can be applied to liquid crystal display devices operable at room temperature.

Novel liquid crystal compounds

Novel ferroelectric liquid crystal compounds showing three stable liquid crystal states so as to give particular optical response wave shape as well as particular optical and electric responses to impressed voltage of triangle wave shape in comparison wit

Liquid crystal compounds having naphthalene nucleus

Novel ferroelectric liquid crystal compounds which may realize a stable molecular orientation which makes it possible to give a definite light-dark contrast in the no electric field state and attain a definite threshold property as well as hysteresis, and for making it possible to attain the dynamic driving as well as the high speed of response, owing to tri-stable phase thereof, of the general formulae (I) and (II) STR1 in which R1 means an alkyl, alkoxy or alkyloxycarbonyl each of 1-20 carbon atoms, R2 means optically active STR2 wherein n is an integer of 4-10, X means STR3 Y means STR4